Loading...
Presentation Type
Clinical Research
Recommended Citation
Ataga, K. I., Derebail, V. K., & Archer, D. R. (2014). The glomerulopathy of sickle cell disease. American Journal of Hematology, 89(9), 907–914. https://doi.org/10.1002/ajh.23771 Gaurav, P., Jones, M., Wierenga, K. J., et al. (2020). Sickle cell disease: Advances in understanding and treatment. Journal of Clinical Investigation, 130(3), 1100–1110. https://doi.org/10.1172/JCI89741 Limou, S., & Dummer, P. D. (2021). Precision medicine for APOL1 kidney disease: A review of pathogenesis and treatment perspectives. Human Molecular Genetics, 30(R1), R129–R137. https://doi.org/10.1093/hmg/ddab091 Ma, L., Nelson, G. W., Friedman, D. J., et al. (2017). APOL1 renal risk variants increase kidney disease in African Americans with SLE. Nature Genetics, 49, 517–523. https://doi.org/10.1038/ng.3782
Impact of APOL1 G1 and G2 Variants on Albuminuria Onset and Treatment Response in Pediatric Sickle Cell Disease